Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

re Today's Roskamp Report - An Update

|Includes: Rock Creek Pharmaceuticals, Inc. (RCPI)

Dr. John L. Faessel


Commentary and Insights


Star Scientific Inc. (CIGX) Nasdaq


A Stock for the Ages – Maybe? Likely!


Part B:

Part C to follow shortly


An Update on Today’s Roskamp Report


Today the Roskamp Institute reported on new studies that further examined the properties of (RCP-006) and how the compound reduces the activity of NF-KB proteins. The graph vividly demonstrates the dramatic effect of RCP-006 compared to Aspirin or Celebrex* in lowering LPS induced NF-KB activity in human white blood cells.

Link at:


Amazingly, the graph shows that (RCP-006) is over eight (8) times more effective that Aspirin and fifteen (15) times more effective that Celebrex in reducing NF-KB activity, i.e. inflammation. More crucially, Aspirin and Celebrex cannot be taken at high enough dosages to sustain “effective” blood levels to reduce inflammation because of toxicity. In medicine / pharmacology this is called the effective or “e” dose necessary to produce the desired therapeutic response. Therefore, what this means is that (RCP-006), trade name Anatabloc™, can be taken without toxicity concerns. And in fact; it is being taken at sustained effective dose levels in numerous ongoing studies.


As I mentioned in yesterday’s report; Star formally announced on 8/9/2011 that Anatabloc™“will be launched before the end of Q3 and it will be introduced to the market via a dedicated website where online purchases can be made, and a toll-free number also will be available for telephone orders.”


Grasp the meaning to mankind of the above information taken in to-to; consumers everywhere will soon be able to purchase an over-the-counter nutritional supplement that they can take daily in sustained, therapeutically effective doses to reduce inflammation. This sounds to me like the Holy Grail of medicine postulated by Dr. Michael Mullen, director of the Roskamp Institute. Patrick Cox of Breakthrough Technologies has said, “I'm convinced that this is one of the most important breakthrough technologies of our time.”


The market for a product to reduce low grade inflammations is of stunning proportions. Chronic inflammation is present in a number of coronary and vascular diseases, and in auto-immune diseases such as thyroid disease, diabetes, arthritis and numerous other conditions. The Roskamp Institute is conducting research using (RCP-006) on Alzheimer’s disease, gastroenterology, rheumatology, cancer, auto-immune diseases (lupus), and cardio-atherogenesis (the process of atheromatous plaque development in arteries), among other conditions.


Well over 100,000 people have now taken (RCP-006) including my wife and myself. Every day I hear anecdotal stories of remarkable successes/healings. The short version is that this compound appears to have extraordinary effects on numerous bodily woes that we all experience, especially in aging. But here's a new one; I get really nasty head colds and especially in the first couple of days my sinuses burn and I get the very runny nose that goes with it. From my experience having an "effective dose" on board made the cold immensely easier to deal with. As I mentioned before I take the compound for my prostate and the results are amazing in that I don't have to get up much at all at night anymore and the flow of urine runs free without any effort.


The commercial “launch” of Anatabloc™ will be orchestrated by marketing giant InVentiv Health (a Thomas H Lee Partners subsidiary), a leading marketing and distribution company with a client list that includes many of the largest, most successful pharmaceutical and biotech companies in the world, including Johnson & Johnson, Abbott Laboratories, Novartis, Merck, Pfizer, and Eli Lilly.  InVentiv, a $2 billion company, has marketing and sales capabilities in 40 countries around the globe. Thomas Lee Partners has invested approximately $22 billion of equity capital in more than 100 businesses with an aggregate purchase price of more than $150 billion.


Just reflect about the scrutiny and due diligence that Star and Anatabloc™ must have gone through by InVentive Health and Thomas Lee Partners before being chosen as a client?


Other studies of (RCP-006) are currently underway at Johns Hopkins School of Medicine, the Flint Study (see press release 2/28/2011). New trials were just announced on (8/9/2011) that will explore the role of  Anatabloc™  in smokers who also have elevated CRP blood levels, and there is a new study on thyroid disease to be conducted at the University of Pisa, Medical School, Pisa, Italy. This study is being shepherded by Dr. Patrizio Caturegli of Johns Hopkins.


On July 25th 2011 the Roskamp Institute posted data on their ‘inflammaging research’ revealing how (RCP-006) is more than four (4) times more effective than either  Celebrex or Voltarol in reducing inflammation in whole human blood. Link:


Previous research from a few months ago demonstrated the dramatic effect of (RCP-006) versus Lipitor, well known to have advanced anti-inflammatory properties. (RCP-006) was shown to be more than three (3) times more effective than Lipitor in reducing inflammation. Lipitor sales in 2010 were $10.7 billion.  Link:

* Celebrex is a powerful non-steroidal anti-inflammatory drug that has helped millions of people and has sold in the $billions and requires a prescription from a physician. Celebrex requires a prescription from a physician. Further, news of side effects has negatively affected sales to a large degree. The National Cancer Institute found that there was an increased risk of heart attack and stroke in persons who took Celebrex for the prevention of colorectal problems.


The Roskamp Institute is funded by the National Institutes of Health and private donations. To view the Institute's home page;


A link of note: TIME Magazine Cover StoryThe Secret Killer: “The Surprising Link between Inflammation and Heart Attacks, Cancer, Alzheimer’s and Other Diseases”, Chronic Inflammation  - the “engine that drives many of the most feared illnesses of middle and old age.”


I have bought shares of Star Scientific in the open market and have no other affiliation with the company than as a shareholder.


If you missed my previous reports—more specific in detail and scope on each of these themes—or wish to receive my Best Ideas for 2011, send a request to: